→ AstraZeneca says that its Phase III ZONDA study of benralizumab hit the primary endpoint, allowing asthma patients to reduce the use of steroids while maintaining control of the disease. “Benralizumab showed an impressive clinical efficacy by reducing exacerbations rate by up to 70% at the same time enabling patients with severe asthma to significantly lower their prednisone dose and maintain their lung function,” said Parameswaran Nair, professor of respiratory medicine at McMaster University in Hamilton, Canada and the lead investigator of the trial.
→ San Diego-based TP Therapeutics has raised $45 million in a Series C. Much of the money is being earmarked for the development of TPX-0005, in the pipeline for cancer patients with ALK, ROS1 or NTRK abnormal genes, as well as several preclinical pipeline projects. The syndicate was led by Lilly Asia Ventures, OrbiMed Advisors, and S.R. One and joined by existing investors Cormorant Asset Management and SV Tech Ventures. “We believe TPX-0005 has the potential to comprehensively address the drug resistance issues associated with acquired resistance mutations from targeting the ALK, ROS1, and NTRK family, and the bypass and EMT mechanisms. With bypass and EMT as common resistance mechanisms in targeted therapies, TPX-0005 has the potential to address drug resistance observed in other therapeutic targets, such as EGFR, via combination therapies,” said Jingrong Jean Cui, founder and CSO. Cui is credited as the lead inventor on crizotinib.
→ Beijing-based CANbridge Life Sciences raised $25 million in a Series B round with lead investor Lapam Capital. The rest of the syndicate includes Qiming Venture Partners, Yuanming Capital, Yanyuan Capital, Biossom Investment Management and Wuxi App Tec. The biotech has two cancer drugs in development.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,400+ biopharma pros who read Endpoints News by email every day.Free Subscription